targeted therapies
Novel targeted therapies for mantle cell lymphoma
... and frequent need for dose reductions, a phase II study of 25 mg weekly of temsirolimus was performed. The ORR was 41% with a median time to progression of 6 months. The authors concluded that the lower dose retained ...
9
Novel oral targeted therapies in inflammatory bowel disease
... oral therapies have the potential to provide a more acceptable, convenient treatment on an individualised ...more targeted immunosuppression thus reducing inflammation, disease progression and associated ...
37
Molecular targeted therapies in metastatic melanoma
... The discovery of activating mutations in serine/threonine kinase, BRAF (v-raf murine sarcoma viral oncogene homolog B1) in 50%–60% of melanomas (superficial spreading type) in 2002 spurred investigations into the ...
8
Ovarian cancer: emerging molecular-targeted therapies
... and chemoresistance, small inhibitors targeting this signaling cascade may have a therapeutic value. Several clinical trials targeting the PI3K/Akt pathway are ongoing, and pan-PI3K inhibitors are currently in phase I ...
8
Novel targeted therapies in chordoma: an update
... Chordomas are rare primary bone neoplasms that typically originate from the spine or skull base. Conventional practice generally involves maximal safe surgical removal, often followed by focused radiation therapy. ...
11
MONOCLONAL ANTIBODY: A MOLECULAR TARGETED THERAPIES FOR CANCER TREATMENT
... toxicities. Targeted therapies affect specific cellular molecular mechanisms promoting cancer cell survival and proliferation, enabling treatment tailored to specific tumour ...(ALL). Targeted ...
16
Targeted therapies to improve CFTR function in cystic fibrosis
... of targeted therapies to be investigated in other areas, such as re- spiratory ...of targeted therapies in this field outside of oncological prob- lems, as most lung diseases are complex and ...
16
Targeted therapies in breast cancer: are heart and vessels also being targeted?
... of targeted therapies designed to block the epidermal growth factor (EGF) family of receptors and antiangiogenic therapies currently under investigation for the treatment of ...the targeted ...
15
The management of cancer in the elderly: targeted therapies in oncology
... called targeted therapy), appears to be promising in this clinical settings especially in view of the limited ...new targeted agents, by inhibiting cancer-specific pathways, would spare normal cells and ...
7
MET in glioma: signaling pathways and targeted therapies
... Although receptor tyrosine kinases (RTKs) possess the roles as key regulators of normal cellular processes, the dysregulation of growth factor signaling pathways via amplification and the mutational activation of ...
13
Current Status of Fibroblast Growth Factor Receptors Targeted Therapies in Breast Cancer
... The relevance of the FGFR/FGF pathway in the development and progression of BC justifies the growing interest in developing new targeted therapies for this pathway [53]. Small inhibitors of FGFR tyrosine ...
29
Dose optimization of oral targeted therapies in oncology
... As said, future research should focus on the added value of routine dose optimization strategies (such as tdm) of oral targeted therapies on clinical outcome to make dose optimization an evidence based ...
92
Vascular-targeted therapies for Duchenne muscular dystrophy
... The previously described cellular events manifest them- selves clinically in a devastating and progressive manner. Despite continuous contractions by the myocardium, the skeletal muscles deteriorate first in individuals ...
12
Targeted therapies for diarrhea-predominant irritable bowel syndrome
... these targeted therapies is able to provide benefit that goes beyond the monosymptomatic relief conferred by conventional ...new therapies are investigated, the effects of specific agents on ...
32
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
... Accumulated evidences strongly suggest that the remarkable genetic heterogeneity of CC may be the result of a complex interplay among different causative factors, some shared by most human cancers while others typical of ...
10
Metastatic gastric cancer – focus on targeted therapies
... of targeted therapies has recently become possible and appears to be ...Other targeted agents in preclinical or early clinical development include mTOR inhibitors, anti c-MET, polo-like kinase 1 ...
10
Targeted therapies for ER+/HER2- metastatic breast cancer
... of targeted therapies against these driver genes, leading to the approval of two new targeted therap- ies: everolimus and palbociclib against mTOR and CDK4/ 6, respectively, in combination with ...
12
Molecularly Targeted Therapies for Dysimmune Neuropathies
... Conventional treatment options, including corticosteroids, intravenous immunoglobulin, or plasma exchange, often fail to treat dysimmune neuropathies, such as chronic inflammatory demyelinating polyneuropathy, multifocal ...
5
Targeted therapies in the management of colorectal carcinoma: role of bevacizumab
... Abstract: Colorectal cancer continues to be an important public health concern, despite improvements in screening and better systemic chemotherapy. The integration of targeted therapies in the treatment of ...
15
Molecularly Targeted Therapies for Malignant Gliomas
... have been considered to provide useful information toward the monitoring of re- sponse of molecularly targeted therapies in solid tumors (58). This method is not applied in MGs, however, because the levels ...
8